Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01885130
Other study ID # GLI.04.SRE.US10232a
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 2012

Study information

Verified date June 2013
Source Galderma R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Determine if Cetaphil Daily Advance Ultra Hydrating Lotion proves to be a contact sensitizer or irritant in certain individuals.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date
Est. primary completion date January 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Not currently under a doctor's care - Free of dermatological or systemic disorder which would interfere with the results - Free of any acute or chronic disease - Will complete a preliminary medical history form and are in general good health - Can read, understand, and sign informed consent Exclusion Criteria: - Under 18 years old - Currently under doctor's care - currently taking any medication - History of acute or chronic disease - Diagnosed with chronic skin allergies - Pregnant or lactating

Study Design


Related Conditions & MeSH terms

  • Determine Sensitivity of Skin to Cetaphil Daily Advance Ultra Hydrating Lotion
  • Hypersensitivity

Intervention

Other:
Cetaphil Daily Advance Ultra Hydrating Lotion
0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Galderma R&D

Outcome

Type Measure Description Time frame Safety issue
Primary area of erythema and edema is measured 9 consecutive 24hr exposures for every Monday, Wednesday, and Friday for 3 consecutive weeks 3 consecutive weeks